Value
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 4.9 |
| P/S | 10.0 |
| EV/EBITDA | 10.0 |
| Fwd P/E | 6.0 |
| PEG | 4.8 |
| Analyst target | 3.0 |
- ▸Forward P/E: 21.4x
- ▸PEG: 1.71
RDY · Why this verdict
Why Dr. Reddy's Laboratories (RDY) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.5/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Dr. Reddy's Laboratories faces a deteriorating fundamental picture with declining revenue of 12% year-over-year, two consecutive earnings misses, a death cross blocking entry, and the stock already priced above analyst targets — making the current setup one of the weakest risk-reward profiles in the healthcare sector despite reasonable absolute valuation multiples.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Dr. Reddy's revenue is declining 12% year-over-year with zero earnings growth score, two consecutive earnings misses of negative 10.5% and negative 2.5%, and an average earnings surprise across four quarters of only 0.85% — indicating the business is not growing and is persistently delivering at or below analyst expectations. Growth breakdown | Revenue growth returns to above 0% year-over-year within 12 months and earnings surprise exceeds 5% for at least 2 of the next 4 quarters. | →Stable |
| CounterGeneric pharmaceutical revenue can be lumpy due to product launch timing and patent cliff dynamics, and a single strong product launch could reverse the current decline without a structural change in the underlying business. | ||
Dr. Reddy's is in a confirmed downtrend with a death cross triggering a hard block on entry, negative price asymmetry of negative 6.5% upside, the stock already above analyst price targets, and the 50-day and 200-day moving averages both pointing lower — creating a confluence of technical signals against near-term price appreciation. V9 | Momentum score rises above 4.5 and the 200-day moving average slope turns positive within 12 months, resolving the confirmed downtrend designation. | →Stable |
| CounterAn RSI that has not yet reached capitulation levels combined with a very modest analyst target gap suggests the downtrend could stabilize quickly if the next earnings report shows any improvement versus the recent miss pattern. | ||
Dr. Reddy's options market shows a put-to-call ratio of 17.33 — an extremely elevated reading indicating that for every call option outstanding, there are more than 17 puts — combined with implied volatility of 122%, suggesting deep bearish conviction from options market participants who are paying a significant premium for downside protection. Options | Put-to-call ratio falls below 5.0 within 12 months, indicating the most extreme bearish options positioning has been unwound as near-term uncertainty resolves. | →Stable |
| CounterAn extremely high put-to-call ratio in a foreign-listed ADR can reflect hedging by institutional holders of the underlying Indian-listed shares rather than directional bearish speculation, potentially overstating the bearish signal. | ||
Dr. Reddy's has a free cash flow quality ratio of only 4% relative to net income — a red flag indicating that nearly all reported net income does not translate to cash generation — which means that even the earnings that beat expectations in prior quarters may not represent economically meaningful cash returns to shareholders. Quality breakdown | Free cash flow as a percentage of net income improves to above 40% within 12 months, indicating that reported earnings are beginning to convert to real cash. | →Stable |
| CounterWorking capital investment in a generic pharmaceuticals business can temporarily suppress free cash flow conversion while the business prepares for product launches or expands inventory to meet anticipated demand, and this can reverse quickly once the investment phase concludes. | ||
Dr. Reddy's revenue is declining 12% year-over-year with zero earnings growth score, two consecutive earnings misses of negative 10.5% and negative 2.5%, and an average earnings surprise across four quarters of only 0.85% — indicating the business is not growing and is persistently delivering at or below analyst expectations.
→StableGrowth breakdown
- Expectation
- Revenue growth returns to above 0% year-over-year within 12 months and earnings surprise exceeds 5% for at least 2 of the next 4 quarters.
CounterGeneric pharmaceutical revenue can be lumpy due to product launch timing and patent cliff dynamics, and a single strong product launch could reverse the current decline without a structural change in the underlying business.
Dr. Reddy's is in a confirmed downtrend with a death cross triggering a hard block on entry, negative price asymmetry of negative 6.5% upside, the stock already above analyst price targets, and the 50-day and 200-day moving averages both pointing lower — creating a confluence of technical signals against near-term price appreciation.
→StableV9
- Expectation
- Momentum score rises above 4.5 and the 200-day moving average slope turns positive within 12 months, resolving the confirmed downtrend designation.
CounterAn RSI that has not yet reached capitulation levels combined with a very modest analyst target gap suggests the downtrend could stabilize quickly if the next earnings report shows any improvement versus the recent miss pattern.
Dr. Reddy's options market shows a put-to-call ratio of 17.33 — an extremely elevated reading indicating that for every call option outstanding, there are more than 17 puts — combined with implied volatility of 122%, suggesting deep bearish conviction from options market participants who are paying a significant premium for downside protection.
→StableOptions
- Expectation
- Put-to-call ratio falls below 5.0 within 12 months, indicating the most extreme bearish options positioning has been unwound as near-term uncertainty resolves.
CounterAn extremely high put-to-call ratio in a foreign-listed ADR can reflect hedging by institutional holders of the underlying Indian-listed shares rather than directional bearish speculation, potentially overstating the bearish signal.
Dr. Reddy's has a free cash flow quality ratio of only 4% relative to net income — a red flag indicating that nearly all reported net income does not translate to cash generation — which means that even the earnings that beat expectations in prior quarters may not represent economically meaningful cash returns to shareholders.
→StableQuality breakdown
- Expectation
- Free cash flow as a percentage of net income improves to above 40% within 12 months, indicating that reported earnings are beginning to convert to real cash.
CounterWorking capital investment in a generic pharmaceuticals business can temporarily suppress free cash flow conversion while the business prepares for product launches or expands inventory to meet anticipated demand, and this can reverse quickly once the investment phase concludes.
Per-dimension breakdown
Quality
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 3.9 |
| ROA | 3.8 |
| Gross margin | 6.6 |
| Op margin | 0.6 |
| Net margin | 6.4 |
| Current ratio | 6.4 |
| FCF quality | 0.3 |
| Moat | 6.1 |
| Piotroski F | 7.8 |
- ▸Earnings quality RED FLAG: 4% FCF/NI
- ▸Strong Piotroski F-Score: 7/9
Growth
0.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 0.0 |
| EPS growth | 0.0 |
- ▸Declining revenue: -12%
Momentum
8.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.7 |
| MACD | 9.3 |
| OBV | 10.0 |
| MA position | 7.5 |
| Volume | 10.0 |
| vol acceleration | 8.3 |
- ▸Overbought (RSI 86)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat/negative + RSI 86 (late-cycle distribution risk)
- ▸Volume surge (2.2x avg) on up move
Sentiment
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 4.6 |
| erm sentiment | 5.5 |
Insider
5.0/10data confidence 50%Peer rank
3.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.0 |
| quality rank | 5.9 |
| growth rank | 0.7 |
Technical
2.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.0 |
| 52w position | 8.2 |
Risk (lower is worse)
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.4 |
| days to cover | 1.9 |
| volatility | 7.9 |
| put call | 8.9 |
| implied vol | 5.5 |
| beta | 10.0 |
| debt equity | 9.2 |
Catalyst
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 2.9 |
| dividend safety | 5.2 |
- ▸Earnings concerns: 2B/2M
- ▸Dividend: 58.0%
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (7)
- MOMENTUM:8.1>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:28d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-1.3=NEGATIVE
Warning (1)
- DEATH_CROSS:momentum=8.1>=5.0 recovering
Reward-to-Risk
-1.33
Upside
-15.4%
Downside
11.6%
Sizing output
AVOID
SetupRECOVERY — Death cross but MACD improving, RSI 86
EdgeNO_EDGE — No clear edge identified
SuitabilityMODERATE — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 4.5 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Momentum at 8.1) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-1.3=NEGATIVE) reinforce the read. Current asymmetry R:R is -1.33 — supplementary context, not the trigger for this path.
The strongest dimensions are Momentum at 8.1, Risk (lower is worse) at 7.4, and Value at 6.1; the weakest are Growth at 0.0, Technical at 2.7, and Peer rank at 3.2. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -1.33 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Dr. Reddy's revenue is declining 12% year-over-year with zero earnings growth score, two consecutive earnings misses of negative 10.5% and negative 2.5%, and an average earnings surprise across four quarters of only 0.85% — indicating the business is not growing and is persistently delivering at or below analyst expectations.
Trip ifRevenue declines by more than 15% year-over-year in any single quarter, indicating the deterioration is accelerating beyond the current 12% decline rate.
- P2Dr. Reddy's is in a confirmed downtrend with a death cross triggering a hard block on entry, negative price asymmetry of negative 6.5% upside, the stock already above analyst price targets, and the 50-day and 200-day moving averages both pointing lower — creating a confluence of technical signals against near-term price appreciation.
Trip ifMomentum score remains below 3.0 for more than 3 consecutive months, confirming the confirmed downtrend is not resolving and price deterioration is ongoing.
- P3Dr. Reddy's options market shows a put-to-call ratio of 17.33 — an extremely elevated reading indicating that for every call option outstanding, there are more than 17 puts — combined with implied volatility of 122%, suggesting deep bearish conviction from options market participants who are paying a significant premium for downside protection.
Trip ifPut-to-call ratio rises above 20, indicating further intensification of bearish options positioning beyond the already-extreme level of 17.33.
- P4Dr. Reddy's has a free cash flow quality ratio of only 4% relative to net income — a red flag indicating that nearly all reported net income does not translate to cash generation — which means that even the earnings that beat expectations in prior quarters may not represent economically meaningful cash returns to shareholders.
Trip ifFree cash flow as a percentage of net income falls below 0% for 2 consecutive quarters, confirming that earnings are generating no real cash and the quality flag is becoming structural.